Researchers at the University of Newcastle are investigating a surprising factor that may worsen lung health: the body’s metabolism. The team has received $1.5 million in federal funding to explore how metabolic elements, including blood sugar levels, body fat, and cholesterol, could be contributing to the challenges faced by Australians suffering from lung diseases.
The initiative, led by Jay Horvat of the Hunter Medical Research Institute’s (HMRI) Immune Health Research Program, will focus on individuals living with asthma and chronic obstructive pulmonary disease (COPD). These conditions are known for causing significant breathing difficulties and have limited treatment options available.
Horvat explained that by targeting metabolic factors that contribute to cell inflammation, the research aims to uncover potential treatment pathways. “By mapping out these connections in detail, we hope to pinpoint which metabolic changes matter most and which interventions, such as diet, lifestyle changes, or targeted therapies, could offer real relief,” he stated.
The study aims to address a critical gap in research, as individuals with asthma and COPD often experience frequent flare-ups that result in hospitalizations, reduced quality of life, and increased healthcare needs. Historically, research has tended to isolate asthma from COPD, leaving a significant void in understanding how these conditions interact and affect patients collectively.
Exploring New Treatment Avenues
The findings from this research could lead to novel treatments focused on reducing inflammation and improving respiratory function. The project, titled Optimising Pulmonary Therapies using ImmunoMetabolic Analyses of Lung disease: The OPTIMAL Study, involves a multidisciplinary team. This includes Dr. Hayley Scott and Dr. Bronwyn Berthon from the University of Newcastle, as well as Professor Lisa Wood and Professor Murray Cairns from HMRI.
Horvat emphasized the importance of the study in providing new strategies for managing symptoms and enhancing daily life for patients. “If we can understand how metabolic health drives lung inflammation, we can develop better strategies to manage symptoms and improve daily life,” he remarked.
As the research progresses, it holds the promise of transforming the approach to lung disease treatment in Australia, potentially alleviating the burdens faced by thousands of individuals dealing with chronic respiratory conditions. The collaboration among experts highlights the commitment to fostering innovative solutions that address the complexities of lung health and disease management.
